Ketohexokinase Inhibitor Improved Liver Insulin Sensitivity
A new trial shows that targeting fructose metabolism may help reduce liver fat in adults with fatty liver disease.
Updated on Oct. 7, 2026 in Weight Loss
A small, randomized trial of 15 participants found that the experimental drug PF-06835919 improved insulin sensitivity in both the liver and adipose tissue. The six-week study, which targeted a specific metabolic pathway, also reduced liver fat content in individuals with metabolic dysfunction-associated steatotic liver disease.
Why it matters
High fructose intake is linked to the development of cardiometabolic conditions, making the regulation of fructose metabolism a key area for potential intervention. This research suggests that inhibiting ketohexokinase may offer a pathway to treat liver-related metabolic dysfunction.
In a randomized crossover trial of 15 adults with metabolic dysfunction-associated steatotic liver disease, treatment with the ketohexokinase inhibitor PF-06835919 for six weeks improved insulin sensitivity and reduced liver fat. These findings are considered preliminary.
The players
ClinicalTrials.gov
A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
The details
The experimental drug PF-06835919 works by inhibiting ketohexokinase, an enzyme involved in the processing of dietary fructose. By modulating this pathway, the intervention reduced intrahepatic lipid and saturated fatty acid content while improving insulin-stimulated glucose disposal. Researchers measured hepatic insulin sensitivity by assessing the suppression of endogenous glucose production, noting that these metabolic improvements occurred even without changes in overall body weight.
Timeline
The pharmacological treatment phase lasted for 6 weeks.
Health Landscape
This research follows a growing trend in hepatology to move beyond general weight loss as the sole treatment for metabolic dysfunction-associated steatotic liver disease. By investigating ketohexokinase inhibition, the study explores a mechanism focused on fructose metabolism rather than weight modulation.
If you are managing metabolic dysfunction-associated steatotic liver disease, you may want to discuss the role of fructose consumption with your physician. This study serves as a scientific advancement in understanding liver metabolism rather than an immediate change to clinical care.
The takeaway
This trial identifies a potential therapeutic target for addressing liver fat and insulin resistance through fructose metabolism. Individuals should continue to monitor their metabolic health markers with their doctor and stay informed as research into enzyme-inhibiting drugs progresses.
Further reading
For broader trends in managing metabolic health, visit our Weight Loss section.
More information
View the complete details of the study in the ClinicalTrials.gov study record.
Source note: This article includes information reported by Nature.
